Discounted Cash Flow

Puma Biotechnology, Inc.

PBYI · Based on 10 years of SEC filings

—

—

Average annual growth rates

Metric 10-Year 5-Year 3-Year
Sales — — —
Free Cash Flow — — —
Average (FCF & NI) — — —
Net Income — — —

Average annual growth is the mean year-over-year change across each period.

Endpoint CAGR (better for long term trend)

Metric 10-Year 5-Year 3-Year
Sales — — —
Free Cash Flow — — —
Average (FCF & NI) — — —
Net Income — — —

Endpoint CAGR is the compound annual rate from the first to last year in each period.

Projections use average year-over-year growth. Change this in Settings.

Projected growth rate

—

Free cash flow growth —
10-year: — 5-year: — 3-year: —
Averaged growth (FCF & NI) —
10-year: — 5-year: — 3-year: —
Net income growth —
10-year: — 5-year: — 3-year: —
Sales growth (not added to calculations) —
10-year: — 5-year: — 3-year: —

Click a greyed-out slider to switch metrics. Slide between the 10-year, 5-year, and 3-year historic growth rates for FCF, net income, or their average.

%
%

Historical inputs (10 fiscal years)

YEAR Sales Net Income Free Cash Flow Net Margin EPS (diluted)
2016 $958.0k $-276.0m $-146.0m -28811.2% $-8.29
2017 $27.7m (2789.9%) $-292.0m (-5.8%) $-172.9m (-18.4%) -1054.6% (96.3%) $-7.85 (5.3%)
2018 $251.0m (806.6%) $-113.6m (61.1%) $-24.5m (85.8%) -45.3% (95.7%) $-2.99 (61.9%)
2019 $272.3m (8.5%) $-75.6m (33.4%) $22.4m (191.1%) -27.8% (38.6%) $-1.95 (34.8%)
2020 $225.1m (-17.3%) $-60.0m (20.6%) $727.0k (-96.7%) -26.7% (4.0%) $-1.52 (22.1%)
2021 $253.2m (12.5%) $-29.1m (51.5%) $20.6m (2740.4%) -11.5% (56.8%) $-29126.00 (-1916084.2%)
2022 $228.0m (-9.9%) $2.0k (100.0%) $-15.8m (-176.6%) 0.0% (100.0%) $0.00 (100.0%)
2023 $235.6m (3.3%) $21.6m (1079450.0%) $26.9m (269.8%) 9.2% (1044603.8%) $0.46
2024 $230.5m (-2.2%) $30.3m (40.2%) $38.9m (44.6%) 13.1% (43.4%) $0.62 (34.8%)
2025 $228.4m (-0.9%) $31.1m (2.8%) $41.7m (7.4%) 13.6% (3.7%) $0.62 (0.0%)

Base FCF: — (latest fiscal year)

Discount rate: %

Terminal growth: —

Projection period: — years

Alt A decline yrs:

Alt B total yrs:

Projected cash flows

Year Projected cash flow Discount Factor Present Value

PV of projected FCF: —

Terminal FCF: —

Terminal value: —

PV of terminal value: —

Enterprise value (DCF): —

DCF price per share: —

Current price: —

Alternative DCF Models

Model Fair Value Upside PV(FCFs) PV(Terminal) Total Years
Standard (10yr→TV) ⓘ — — — — 10 + TV
Alt A (Gradual Decline) ⓘ — — — — —
Alt B (30yr Hard Stop) ⓘ — — — N/A —

This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.

+ 10YR Financials Balance Sheet (10YR) Cash Flow (10YR) DCF Model